Physician profile
Deetu K Simh
NPI 1073704425
$939.15
in general payments reported to CMS, 2019-2025
15 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.57 · 2020: $19.70 · 2021: $114 · 2022: $124 · 2023: $95.70 · 2024: $255 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639 · Education: $24.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.22 |
| Education | $24.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $149.20 | 2024-2025 | Tarpeyo |
| Amgen INC. | $121.28 | 2019-2025 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $98.71 | 2023-2025 | Jynarque |
| Vifor Pharma, INC. | $93.75 | 2021-2023 | Veltassa |
| Glaxosmithkline, LLC. | $88.43 | 2023-2025 | Benlysta, Jesduvroq |
| Astrazeneca Pharmaceuticals LP | $84.10 | 2021 | |
| Baxter Healthcare | $70.59 | 2022 | |
| Akebia Therapeutics INC | $68.75 | 2021-2024 | Auryxia, Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $62.59 | 2024 | |
| Novartis Pharmaceuticals Corporation | $23.54 | 2025 | |
| Fresenius USA Marketing, INC. | $19.70 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.05 | 2025 | Jardiance |
| Novo Nordisk INC | $18.28 | 2025 | Ozempic |
| Genzyme Corporation | $16.75 | 2024 | |
| Travere Therapeutics, INC. | $4.43 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deetu Simh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.